ArticleFrontiers in nutrition2026
Total body water to lean body mass ratio predicts mortality in patients with chronic heart failure: a prospective, observational study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malnutrition and sodium water retention are some of the most common complications of chronic heart failure (CHF). To date, several parameters or risk stratification tools have been established to predict one's volume or nutritional status. Unfortunately, there is no biomarker that may reflect both conditions, thus, in this study, we established a novel biomarker known as total body water (TBW) to lean body mass ratio (LBM) ratio (TLR). Accordingly, we also assessed the prognostic value of TLR in CHF patients. Methods: A total of 401 consecutive patients with CHF from August 2019 to October 2021 were prospectively enrolled. TBW and LBM were obtained by InBody S10. The primary endpoint was long-term all-cause and cardiovascular mortality. The cut-off and prognostic value of TLR was determined by receiver operating characteristic curves and Cox regression analysis. Patients were then divided into two groups according to the cut-off value of TLR. Results: During a median follow-up of 1,200 days, the high-TLR group (TLR ≥ 0.783) was presented with a higher all-cause mortality (41.27% vs. 18.40%, Conclusion: The TLR may serve as a novel composite biomarker that reflects both volume and nutritional status in CHF patients and is associated with long-term prognosis. Its prognostic performance appears comparable to several established biomarkers, though further validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.